Vet Med - Czech, 2025, 70(11):401-407 | DOI: 10.17221/25/2025-VETMED

Efficacy of a new ready-to-use PCV2 and Mycoplasma hyopneumoniae vaccine under field conditionsOriginal Paper

P Trampus1, A Csagola1, T Szalai1, N Palmai1, A Toth1, N Terenyi1, Z Nagy1, NA Szeplaki1, G Somogyi1, E Rausch1, Z Penzes1, R Krejci2
1 Ceva-Phylaxia Zrt., Budapest, Hungary
2 Ceva Santé Animale, Libourne Cedex, France

Coinfection of porcine circovirus type 2 (PCV2) with Mycoplasma hyopneumoniae (M. hyo) causes major worldwide economic losses within the swine industry. This study aimed to assess the safety and efficacy of a single dose of a bivalent vaccine containing PCV2d and M. hyo antigen (Cirbloc® M Hyo) under field conditions. Two studies were performed under the GCP (Good Clinical Practice) requirements on farrow-to-finish farms in Hungary and Cyprus. On both farms, the presence of both PCV2 and M. hyo infection was demonstrated. For both studies, safety parameters were observed and measured from inclusion at 21 (±3) days of age until 14 days after vaccination. Efficacy parameters were observed and measured from inclusion until slaughter. Administration of the vaccine was safe in both studies, as no general, immediate, or local reactions were observed. The efficacy of the vaccine was confirmed in both studies as the following parameters were significantly reduced in the vaccinated groups compared to the control groups: viraemia, faecal shedding, viral load in lungs and in all collected lymphoid tissues, M. hyo-specific lung lesions, and average daily body weight gain. These results collectively support the vaccine’s potential as an effective tool for disease control.

Keywords: bivalent; immunisation; PCV2d; PRDC; trial; swine

Received: April 4, 2025; Revised: August 6, 2025; Accepted: August 15, 2025; Prepublished online: November 27, 2025; Published: November 28, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trampus P, Csagola A, Szalai T, Palmai N, Toth A, Terenyi N, et al.. Efficacy of a new ready-to-use PCV2 and Mycoplasma hyopneumoniae vaccine under field conditions. Vet Med - Czech. 2025;70(11):401-407. doi: 10.17221/25/2025-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allan G, Krakowka S, Ellis J. PCV2: Ticking time bomb. Pig Prog. 2002;18(1):22-5.
    2. Blanchard B, Vena MM, Cavalier A, Le Lannic J, Gouranton J, Kobisch M. Electron microscopic observation of the respiratory tract of SPF piglets inoculated with Mycoplasma hyopneumoniae. Vet Microbiol. 1992 Mar;30(4):329-41. Go to original source... Go to PubMed...
    3. Brunborg IM, Moldal T, Jonassen CM. Quantitation of porcine circovirus type 2 isolated from serum/plasma and tissue samples of healthy pigs and pigs with postweaning multisystemic wasting syndrome using a TaqMan-based real-time PCR. J Virol Methods. 2004 Dec;122(2):171-8. Go to original source... Go to PubMed...
    4. Chae C. Porcine respiratory disease complex: Interaction of vaccination and porcine circovirus type 2, porcine reproductive and respiratory syndrome virus, and Mycoplasma hyopneumoniae. Vet J. 2016 Jun;212:1-6. Go to original source... Go to PubMed...
    5. Clark EG. Post-weaning multisystemic wasting syndrome. In: Proceedings of the Western Canadian Association of Swine Practitioners. Saskatoon, SK: Western Canadian Association of Swine Practitioners; 1996. p. 22-5.
    6. Duivon D, Correge I, Hemonic A, Rigaut M, Roudaut D, Jolie R. Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm. Porcine Health Manag. 2018 Jan 18;4:4. Go to original source... Go to PubMed...
    7. Eddicks M, Eddicks L, Stadler J, Hermanns W, Ritzmann M. Der porcine respiratorische Krankheitskomplex (PRDC) - eine klinische Ubersicht [The porcine respiratory disease complex (PRDC) - A clinical review]. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2021 Apr;49(2):120-32. German. Go to original source... Go to PubMed...
    8. Franzo G, Segales J. Porcine circovirus 2 genotypes, immunity and vaccines: Multiple genotypes but one single serotype. Pathogens. 2020 Dec 14;9(12):1049. Go to original source... Go to PubMed...
    9. Guo J, Hou L, Zhou J, Wang D, Cui Y, Feng X, He C, Li X, Yin Y, Li H. Porcine circovirus type 2 vaccines: Commercial application and research advances. Viruses. 2022 Sep 9;14(9):2005. Go to original source... Go to PubMed...
    10. Halbur P. Changing trends in the porcine respiratory disease complex. In: Proceedings of the National Pork Producers Council Pork Summit. Des Moines, IA: National Pork Producers Council; 1996.
    11. Harding JC. Post-weaning multisystemic wasting syndrome (PMWS): Preliminary epidemiology and clinical presentation. In: Proceedings of the Western Canadian Association of Swine Practitioners. Saskatoon, SK: Western Canadian Association of Swine Practitioners; 1996. p. 21.
    12. Harding JC. Porcine circovirus diseases (PCVD): The brutal facts. In: Proceedings of the Annual Meeting of the American Association of Swine Veterinarians. Orlando, FL: American Association of Swine Veterinarians; 2007. p. 4.
    13. Lopez-Lorenzo G, Prieto A, Lopez-Novo C, Diaz P, Lopez CM, Morrondo P, Dieguez FJ. Efficacy of two commercial ready-to-use PCV2 and Mycoplasma hyopneumoniae vaccines under field conditions. Animals (Basel). 2021 May 26;11(6):1553. Go to original source... Go to PubMed...
    14. Segales J. Porcine circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis. Virus Res. 2012 Mar;164(1-2):10-9. Go to original source... Go to PubMed...
    15. Sipos W, Sipos S. Clinical efficacy of two novel, differentially administered (IM, ID) vaccines against Mycoplasma hyopneumoniae and PCV2 in swine under field conditions. Animals (Basel). 2022 Dec 8;12(24):3467. Go to original source... Go to PubMed...
    16. Thacker EL. Immunology of the porcine respiratory disease complex. Vet Clin North Am Food Anim Pract. 2001 Nov;17(3):551-65. Go to original source... Go to PubMed...
    17. Thacker EL, Minion FC. Mycoplasmosis. In: Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, editors. Diseases of swine. 10th ed. Ames, IA: Wiley-Blackwell; 2012. p. 779-98.
    18. Tzika ED, Tassis PD, Koulialis D, Papatsiros VG, Nell T, Brellou G, Kritas SK. Field efficacy study of a novel ready-to-use vaccine against Mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm. Porcine Health Manag. 2015 Dec 15;1:15. Go to original source... Go to PubMed...
    19. Xiao CT, Halbur PG, Opriessnig T. Global molecular genetic analysis of porcine circovirus type 2 (PCV2) sequences confirms the presence of four main PCV2 genotypes and reveals a rapid increase of PCV2d. J Gen Virol. 2015 Jul;96(Pt 7):1830-41. Go to original source... Go to PubMed...
    20. Xiao CT, Harmon KM, Halbur PG, Opriessnig T. PCV2d-2 is the predominant type of PCV2 DNA in pig samples collected in the U.S. during 2014-2016. Vet Microbiol. 2016 Dec 25;197:72-7. Go to original source... Go to PubMed...
    21. Yang S, Ahn Y, Oh T, Cho H, Park KH, Chae C. Field evaluation of a single-dose bivalent vaccine of porcine circovirus type 2b and Mycoplasma hyopneumoniae. Vet Med Sci. 2021 May;7(3):755-65. Go to original source... Go to PubMed...
    22. Yang S, Oh T, Mago J, Iwakuma A, Chae C. Optimal vaccination strategy against Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus, and porcine circovirus type 2 in case of early M. hyopneumoniae infection. Vet Med Sci. 2020 Nov;6(4):860-74. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content